RESEARCH · INTERNATIONAL CONFERENCE ABSTRACT (ORAL)

Oral tranexamic acid and glutathione to prevent pigmentation and phlebitis after MOCA: a retrospective comparison

Adjunctive Oral Tranexamic Acid and Glutathione for Prevention of Hyperpigmentation and Phlebitis after Mechanochemical Ablation: A Retrospective Comparative Study

Presenter & coauthor
Dongju Seo, Byungkwon Chung (Darefit Clinic, Korea)
Society / meeting
Asian Venous Forum 2026, Fukushima, Japan (Corasse Fukushima)
Session
JSP International Session 3 (v-WIN Award), 11:10–12:00 · Abstract IS-3-2
Presentation date
Record type
International conference abstract (oral) — not a peer-reviewed journal article

Purpose

Pigmentation and superficial phlebitis after MOCA (ClariVein) can cause dissatisfaction, especially in Asian patients with Fitzpatrick III–IV skin. This study assessed whether oral tranexamic acid (TXA) plus glutathione (GSH) might reduce these problems proactively rather than treating them only after onset.

Methods

  • Single-center retrospective comparison; one operator
  • 60 higher-risk patients (Fitzpatrick III–IV; pigmentation history; superficial tributary involvement)
  • Intervention group, 32 patients from January 2025: TXA 250–500 mg/day plus GSH 500 mg/day for 2–4 weeks after treatment (study regimen)
  • Historical controls, 28 patients: standard care without adjunct medication
  • At four weeks: complication occurrence, clinical severity, ImageJ color difference (ΔE) and patient satisfaction

Reported findings

  • Complications: 9.3% in the intervention group vs. 25.0% in controls (about 62% relative reduction as stated in the abstract)
  • Intervention-group events were described as milder: faint, temporary pigmentation and phlebitis without tenderness
  • Lower ΔE values in the intervention group on ImageJ analysis
  • No thrombotic adverse events observed at the reported TXA dose

Limitations

  • A conference abstract, not a full peer-reviewed journal article.
  • No randomization; controls came from an earlier period. Changes in operator experience or care over time may have influenced results.
  • Only 60 participants; the abstract does not report tests of statistical significance.
  • Four weeks is too short to assess long-term outcomes or rare adverse effects.
  • One center and one operator limit application to other settings.

This page summarizes a conference abstract. Its findings do not guarantee any treatment’s effect. Care decisions require individual examination.

Related materials